Agilent Technologies (NYSE: A) reported third-quarter revenue of $1.88bn on Wednesday, beating its own guidance and lifting shares to a 20-day high.
The figure marks 7.3% growth on a core basis, topping the company’s guidance by 140 basis points, according to Zacks. Shares closed at $160.05, up 4.55% on the day and near the stock’s 20-day high of $161.00.
Margins hold up despite tariff noise
Operating margin, excluding tariff refunds, came in at 27.2%, with earnings per share of $1.56 on the same ex-tariff basis, beating guidance by $0.06, as first reported by Benzinga. Executives credited the company’s IGNITE operating system for the margin improvement, according to the earnings call transcript.
Growth was not evenly spread. Pharma revenue rose 12%, driven by GLP-1 drug demand and expansion in Agilent’s Advanced Therapeutics division, MarketBeat reported. China sales grew 9%, well ahead of a flat forecast, on strength in pharma and food-testing demand.
Guidance raised for the full year
Agilent lifted its full-year revenue growth outlook to a range of 5.8% to 6%, with earnings per share now guided at $6.18 to $6.21, according to a transcript published by Seeking Alpha. Management pointed to broader end-market confidence as the basis for the upgrade.
Trading volume around the report ran at 1.38 times the 20-day average, and the stock is up 14.62% over the trailing 20 days, according to consolidated exchange data cited by Benzinga. FINRA’s daily short-sale data show the short-volume ratio for Agilent jumped to 0.639 on the day of the results, up from 0.315 two trading sessions earlier, though that ratio measures same-day short-sale activity rather than a net short position and can swing sharply around scheduled news.
The longer run of results
The reported quarter builds on a run of steady, if unspectacular, top-line growth. Agilent’s most recent structured filing with the US Securities and Exchange Commission showed second-quarter revenue, covering February to April 2026, of $1.835bn, up from $1.798bn in the preceding quarter, according to the company’s 10-Q filing. Diluted earnings per share for that quarter were $1.20, versus $1.07 three months earlier.
A year earlier, in the quarter ended July 2025, Agilent reported revenue of $1.738bn and diluted EPS of $1.18, per its filing from August 2025. That comparison base underlines the scale of the jump now being reported for the equivalent quarter this year, when growth accelerated well beyond the mid-single-digit pace the company had posted through most of fiscal 2024 and 2025. Net income across those prior quarters ranged from $215m to $348m, a band the market will watch for confirmation once Agilent files its formal quarterly report with underlying GAAP figures.
Agilent has typically published detailed results as an exhibit to an 8-K filing alongside its earnings call, a pattern evident in its first-quarter release filed with the SEC in March. Investors will be watching for that same filing discipline to apply to the third-quarter numbers detailed on Wednesday’s call, which would allow the core-basis growth rate and segment breakdowns to be checked against the company’s full financial statements.
Wider market backdrop
The rally in Agilent shares came against a backdrop of easing US Treasury yields, with the 10-year yield at 4.64% as of 25 August, down from 4.70% previously, according to Federal Reserve data. The 2-year yield stood at 4.17%, versus 4.24% prior, while the unemployment rate held at 4.1% in July, edging down from 4.2% the month before, per Federal Reserve figures. Lower short-end yields and a stable labour market have generally supported risk appetite for growth-sensitive industrial and life-sciences names this year.
Attention now turns to whether Agilent’s China growth, which beat a flat forecast by a wide margin, can be sustained into the fourth quarter, and to the formal SEC filing that would let analysts test the core-versus-reported growth distinction management outlined on the call.
This article is for information only and is not investment advice or a recommendation to buy or sell any asset. Markets move quickly; figures are correct as sourced at the time of writing. Always do your own research before making financial decisions.
